---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-040786"
form_type: "8-K"
ticker: "RNXT"
cik: "0001574094"
company_name: "RenovoRx, Inc."
filed_at: "2023-11-14T23:59:59+00:00"
generated_at: "2026-06-08T03:34:02.936216+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# RenovoRx Q3 net loss narrows to $1.4M on warrant gain; TIGeR-PaC trial advances

## Summary
- Net loss of $1.4M vs $2.1M YoY; includes $1.5M gain on fair value of common warrants.
- Cash and equivalents $3.2M as of Sept 30, 2023; shares outstanding 10.7M.
- R&D expense $1.6M, up 100% YoY, driven by Phase III TIGeR-PaC trial costs.
- Phase III TIGeR-PaC trial for pancreatic cancer continues after interim analysis recommended continuation.
- Collaboration with Imugene to expand TAMP platform into immunotherapy.

## SEC filing metadata
- accession: 0001493152-23-040786
- form_type: 8-K
- ticker: RNXT
- cik: 0001574094
- company_name: RenovoRx, Inc.
- filed_at: 2023-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1574094/000149315223040786/0001493152-23-040786-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1574094/000149315223040786/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-040786
- JSON: https://secwatch.observer/filing/0001493152-23-040786.json
- Plain text: https://secwatch.observer/filing/0001493152-23-040786.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.